Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 4/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005902 | 0.91 | VEGFA (0.53) | VEGFAEGLN1GRIN2BALDH1A1COMT | |
| SCHEMBL17005857 | 0.89 | VEGFA (0.53) | VEGFAEGLN1GRIN2BALDH1A1MEN1 | |
| SCHEMBL17005896 | 0.89 | VEGFA (0.53) | VEGFAEGLN1GRIN2BALDH1A1GAA | |
| SCHEMBL17005957 | 0.87 | VEGFA (0.61) | VEGFAEGLN1ALDH1A1GAAMEN1 | |
| SCHEMBL28567439 | 0.86 | VEGFA (0.68) | VEGFAEGLN1GRIN2BCOMT | |
| SCHEMBL17005959 | 0.85 | VEGFA (0.66) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL17005890 | 0.84 | VEGFA (0.61) | VEGFAEGLN1GRIN2BALDH1A1GAA | |
| SCHEMBL17005874 | 0.84 | VEGFA (0.64) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL17005850 | 0.83 | VEGFA (0.60) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL17005847 | 0.83 | VEGFA (0.56) | VEGFAEGLN1ALDH1A1GAACOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107542-B1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | VEGFA 4681/4885EGLN1 102/4885GRIN2B 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.